neurocare group AG receives EUR 19.3 million investment from Impact Expansion and TVM Capital Healthcare
February 5, 2025 - neurocare group
Munich, Brussels, Riyadh – February 5th, 2025 - neurocare group AG (“neurocare” or the “Company”), a leading mental health platform, is pleased to announce a EUR19.3 million investment from Impact Expansion, an impact driven European private equity firm based in Luxembourg with offices in Brussels and Paris and from existing neurocare shareholder TVM Capital Healthcare. This investment demonstrates strong confidence in neurocare’s strategy and supports the company’s continued global growth.
This funding will enable neurocare to further develop its technologies and services as well as expand its international footprint of mental health clinics.
neurocare´s best practice mental health platform empowers clinicians to provide personalized treatment for a range of psychological or neurological conditions. The platform integrates innovative mental health care methods and tools such as sleep hygiene, rTMS, QEEG and neurofeedback with existing approaches such as talk therapy and pharmaceuticals. These assets are all embedded within a cloud-based solution to drive productivity and improve outcomes. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing individualized therapy plans, scientifically proven to deliver superior clinical outcomes for Depression, ADHD, mental performance and other indications.
According to the World Health Organization, globally 12.9% of people are affected by mental disorders, with associated costs projected to rise from $2.5 trillion in 2010 to $6 trillion by 2030. During the COVID pandemic, diagnoses of mental illnesses doubled, yet access to adequate treatment remains limited in many countries. This gap highlights a significant growth opportunity for neurocare providing innovative, non-invasive treatments with superior clinical outcomes by empowering clinicians to deliver best practice.
Erick Rinner, Partner, Impact Expansion, stated: “We firmly believe that neurocare is uniquely positioned to lead the way in addressing the growing global mental health crisis. Their care infrastructure and innovative best-practice mental health platform represents a much-needed and timely advancement in the industry. We look forward to supporting Thomas and his management team to become a leading force within the mental health care sector.”
Tristan de Boysson, Managing Partner, TVM Capital Healthcare, added: "Our continued investment in neurocare is a clear reflection of our confidence in their vision and progress. We are excited to further support their efforts in delivering effective mental health solutions globally, and particularly, in markets such as Saudi Arabia with tremendous growth prospects for specialty care and government support for improving access to mental healthcare.”
Thomas Mechtersheimer, Founder and CEO of neurocare group, said: “This investment by another internationally renowned impact investor plus a follow-on investment from TVM Capital Healthcare is a strong endorsement of our progress and reinforces the confidence in our executive team and strategy. We will now drive the company’s growth and empower many more clinicians to support many more patients with our best practice platform."
About Impact Expansion
Impact Expansion is an investment manager sponsored by KOIS, a pioneer in impact investing, which currently manages circa €500 million in impact-focused private equity. Impact Expansion operates from its offices in Brussels and Paris, with the mission to invest in businesses that align with three strategic themes:
- Skilling & Inclusion – investing in sectors like education, training, social inclusion, and youth employment to combat long-term unemployment and isolation.
- Climate & Nature – supporting companies that offer solutions to environmental challenges related to the climate crisis, pollution, and biodiversity loss, while promoting the circular economy.
- Health & Well-being – focusing on improving access to high-quality care.
Impact Expansion manages a €150m fund that takes both minority and majority stakes, investing between €5 and €30 million in companies based in Western Europe. By leveraging deep expertise in impact investing alongside disciplined private equity practices, the team aims to achieve outstanding social and environmental outcomes while delivering top-tier financial returns.
About TVM Capital Healthcare
TVM Capital Healthcare is an emerging markets-focused healthcare private equity firm headquartered in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City. The Firm invests expansion and growth capital in healthcare companies to improve local access to quality care. Investment and operating partners as well as a strong group of senior advisors have long-standing international track records in healthcare investing, active board work, contributions to strategy development and implementation, and deep healthcare operations experience. The firm partners with local Middle Eastern and Southeast Asian management teams to build domestic or regional sector champions and selectively back companies from Europe or North America for expansion into the firm’s two key target geographies. TVM Capital Healthcare’s investment and operating approach combines strong commercial value creation and returns with impact and responsible (ESG) investing.
About neurocare group
neurocare group AG has developed a best practice mental health platform, empowering clinicians to offer their patients, through personalized therapy, the best care for a variety of psychological or neurological conditions with more sustainable clinical outcomes. These therapy plans integrate innovative methods and tools, such as psychotherapy, neuromodulation and sleep hygiene, as well as medication. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing personalized therapy plans that improve self-regulation, resilience and social skills, while being cost-effective for the healthcare system.
The key technology elements of neurocare’s platform are developed in-house, including leading TMS and EEG devices, a cloud-based software platform, as well as an online academy to give professionals the tools and neuroscientific understanding to properly apply these solutions in clinical practice.
neurocare’s mental health platform is currently applied throughout the company’s own clinics across the US, the UK, the Netherlands and Australia, as well as in a growing number of third-party clinics.
Contact:
Sally Remington
neurocare group AG
